Next Step in Clementia's Clinical Program for FOP

Enrollment information and FAQs

The IFOPA is pleased to share the announcement and new FAQs from Clementia Pharmaceuticals regarding the palovarotene clinical trial.

To read the announcement click Next Step in Clementia’s Clinical Program for FOP.

To read the new FAQs click Frequently Asked Questions.

Make a Difference

Donate Connect Fundraise

Already a Member? Sign In

Sign Up for FOP Connection, Our Monthly eNewsletter